Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

van Vollenhoven, R; Voskuyl, A; Bertsias, G; Aranow, C; Aringer, M; Arnaud, L; Askanase, A; Balážová, P; Bonfa, E; Bootsma, H; Boumpas, D; Bruce, I; Cervera, R; Clarke, A; Coney, C; Costedoat-Chalumeau, N; Czirják, L; Derksen, R; Doria, A; Dörner, T; Fischer-Betz, R; Fritsch-Stork, R; Gordon, C; Graninger, W; Györi, N; Houssiau, F; Isenberg, D; Jacobsen, S; Jayne, D; Kuhn, A; Le Guern, V; Lerstrøm, K; Levy, R; Machado-Ribeiro, F; Mariette, X; Missaykeh, J; Morand, E; Mosca, M; Inanc, M; Navarra, S; Neumann, I; Olesinska, M; Petri, M; Rahman, A; Rekvig, OP; Rovensky, J; Shoenfeld, Y; Smolen, J; Tincani, A; Urowitz, M; van Leeuw, B; Vasconcelos, C; Voss, A; Werth, VP; Zakharova, H; Zoma, A; Schneider, M; Ward, M.
A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS).
Ann Rheum Dis. 2017; 76(3):554-561 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG


Autor/innen der Med Uni Graz:
Graninger Winfried

Dimensions Citations:

Plum Analytics:
Treat-to-target recommendations have identified 'remission' as a target in systemic lupus erythematosus (SLE), but recognise that there is no universally accepted definition for this. Therefore, we initiated a process to achieve consensus on potential definitions for remission in SLE. An international task force of 60 specialists and patient representatives participated in preparatory exercises, a face-to-face meeting and follow-up electronic voting. The level for agreement was set at 90%. The task force agreed on eight key statements regarding remission in SLE and three principles to guide the further development of remission definitions:1. Definitions of remission will be worded as follows: remission in SLE is a durable state characterised by …………………. (reference to symptoms, signs, routine labs).2. For defining remission, a validated index must be used, for example, clinical systemic lupus erythematosus disease activity index (SLEDAI)=0, British Isles lupus assessment group (BILAG) 2004 D/E only, clinical European consensus lupus outcome measure (ECLAM)=0; with routine laboratory assessments included, and supplemented with physician's global assessment.3. Distinction is made between remission off and on therapy: remission off therapy requires the patient to be on no other treatment for SLE than maintenance antimalarials; and remission on therapy allows patients to be on stable maintenance antimalarials, low-dose corticosteroids (prednisone ≤5 mg/day), maintenance immunosuppressives and/or maintenance biologics.The task force also agreed that the most appropriate outcomes (dependent variables) for testing the prognostic value (construct validity) of potential remission definitions are: death, damage, flares and measures of health-related quality of life. The work of this international task force provides a framework for testing different definitions of remission against long-term outcomes. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to
Find related publications in this database (using NLM MeSH Indexing)
Adrenal Cortex Hormones - therapeutic use
Antibodies, Antinuclear - blood
Antimalarials - therapeutic use
Complement System Proteins - metabolism
Consensus -
DNA - immunology
Humans -
Immunosuppressive Agents - therapeutic use
Lupus Erythematosus, Systemic - blood
Lupus Erythematosus, Systemic - drug therapy
Maintenance Chemotherapy -
Remission Induction -
Severity of Illness Index -
Symptom Flare Up -

© Meduni Graz Impressum